FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Jacobs Bruce N.</u>						2. Issuer Name and Ticker or Trading Symbol Kymera Therapeutics, Inc. [KYMR]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
(Last)	`	rst) (Middle) ERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/27/2024								below	, ,	Other (s below) ncial Officer		pecify	
500 NORTH BEACON STREET, 4TH FLOOR					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person					
(Street) WATER	ГOWN М	1A	02472												iled by Mor		one Report		
(City) (State) (Zip)				_ R	Rule 10b5-1(c) Transaction Indication														
											nction was n			ract, instruction 10.	on or written	plan tha	at is intended	to	
		Tab	ole I - Nor	n-Deri	vativ	e Se	curit	ies Ac	quired,	Dis	posed o	f, or Be	neficial	ly Owned	l				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,			Code	Transaction Dispo		rities Acquired (A) o ed Of (D) (Instr. 3, 4		Benefic Owned	es ally Following	Form:	Direct Control of the	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	ount (A) or (D)		Reporte Transac (Instr. 3	tion(s)			Instr. 4)	
Common Stock 06/27/					27/202	2024		M		25,00	0 A	\$2.0	8 168	168,554(1)		D			
		•	Table II -								osed of, onverti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$2.08	06/27/2024			М			25,000	(2)	(08/28/2029	Common Stock	25,000	\$0.00	104,89	9	D		

Explanation of Responses:

- $1.\ This\ number\ includes\ 1,203\ shares\ acquired\ under\ the\ Registrant's\ employee\ stock\ purchase\ plan\ on\ June\ 1,\ 2024.$
- 2. Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

/s/ Bruce N. Jacobs

06/28/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.